Haemonetics has announced the full market release of its mid-bore venous closure system, Vascade MVP XL, in the US.
The system, now available to hospitals in the country, is part of the Vascade portfolio and features an expanded use of collagen and a larger disc, catering to procedures using 10–12F sheaths, such as cryoablation, pulsed field ablation (PFA) and left atrial appendage closure (LAAC).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Vascade MVP XL system uses a larger disc and 58% more collagen than its predecessor, the Vascade MVP system.
Since its limited market release in June 2024, the Vascade MVP XL system has been adopted by approximately 80 physicians in more than 30 hospitals.
The system aims to facilitate rapid hemostasis with its unique collapsible disc technology and resorbable collagen patch.
Haemonetics Global Hospital president Stew Strong said: “We received overwhelmingly positive feedback during our limited market release and we are excited to make Vascade MVP XL available to physicians at all US hospitals as soon as possible.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“With our full market release under way and an ongoing clinical trial programme to broaden the indications for this device to even larger access points, Vascade MVP XL will complement our Interventional Technologies portfolio, and underscore our aspiration to be the go-to leader in vascular closure.”
Haemonetics’ Vascade portfolio also includes the original Vascade system for small-bore femoral arterial and venous closure and the Vascade MVP system for mid-bore multi-access femoral venous closure.
The company’s technology addresses key medical markets: the surgical suite and hospital transfusion services and blood and plasma component collection.
